Company intelligence / Profile preview

Nightingale Health

Helsinki, Finland

Ownership: Private
Employees: ~51
Development stage: Other

Overview

Nightingale Health’s proprietary NMR-based technology, clinically validated in more than 600 peer-reviewed publications and used by over 200 institutions globally, can predict risk for multiple chronic diseases from a single blood sample. Its 'Health Check' product is in commercial use, including nationwide healthcare and population-level disease risk screening. The company is expanding direct-to-consumer and at-home testing and opening new diagnostic labs globally.[2][3][6]

Therapeutic areas: EndocrinologyMetabolic DisordersCardiovascularOther
Modalities: Diagnostic platformDevice
Industry: Metabolite Diagnostics

Partnerships

Kaiser FoundationZOEBoston Heart Diagnostics23andMePhenome HealthSuomen Terveystalo OyInnoquest DiagnosticsUK Biobank

Beyond the preview

Go deeper on Nightingale Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nightingale Health.

Explore the full profile